spacer
home > epc > summer 2002 > global edc adoption
PUBLICATIONS
European Pharmaceutical Contractor

Global EDC Adoption

Internet electronic data capture (EDC) is now established as an effective way of conducting clinical trials. Faster access to cleaner data, a more streamlined and less batch-based process and faster database lock are driving real benefits for trial sponsors, leading to a growing acceptance that EDC can be a better way of running studies.

With regions such as South America and Asia Pacific rapidly developing as areas for clinical trials based on the growing importance of these markets to pharma companies, and the adoption of international standards for conducting clinical research, are EDC studies a realistic option for global studies? In fact, online Internet EDC actually facilitates running studies across a number of geographically dispersed countries.

The unique capability to remotely access and centrally manage data as it rapidly accumulates from sites around the world removes the delays and costs inherent in the traditional labour-intensive paper shipping processes. As Internet use spreads rapidly throughout the world, the barriers to deploying EDC are quickly disappearing, making this an increasingly attractive approach for sponsors. There are now many examples of successful EDC trials running beyond the traditional areas of the US and Europe, including sites in Eastern Europe, Africa, Asia Pacific and China.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mark Wren, Director of eService and Support, and Martin Young, Professional Services Director for Phase Forward

Mark Wren brings to Phase Forward over 15 years' experience of successfully implementing technology to the drug development process from both a sponsor and a vendor perspective. Prior to joining Phase Forward, Mark was Director of Clinical Trial Services at Dendrite International where he successfully implemented e-clinical trials systems for many of the large pharmaceutical companies. He has also held managerial positions at the Celltech Group and British Biotech.

Martin Young is Professional Services Director for Phase Forward, responsible for international consulting services and major technology transfer clients. Since establishing Phase Forward's international operations in 1999, Martin has been involved in building the international business and, following the Clinsoft acquisition in 2001, integrating both companies' operations outside North America. Over the past 18 years, Martin has undertaken a number of commercial, IT and re-engineering roles within the IT and pharmaceutical industries. Prior to joining Phase Forward, he worked for Glaxo Wellcome, leading internal and external ventures focused on improving the development process. Martin has a degree in Engineering Science and an Executive MBA.

spacer
Mark Wren
spacer
spacer
spacer
Martin Young
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement